Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-104547
Filing Date
2026-03-13
Accepted
2026-03-12 18:12:12
Documents
100
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K nktr-20251231.htm   iXBRL 10-K 3549532
2 EX-19.1 nktr-ex19_1.htm EX-19.1 215847
3 EX-21.1 nktr-ex21_1.htm EX-21.1 1687
4 EX-23.1 nktr-ex23_1.htm EX-23.1 12607
5 EX-31.1 nktr-ex31_1.htm EX-31.1 13659
6 EX-31.2 nktr-ex31_2.htm EX-31.2 13766
7 EX-32.1 nktr-ex32_1.htm EX-32.1 11288
8 EX-97 nktr-ex97.htm EX-97 42668
9 GRAPHIC img254109253_0.jpg GRAPHIC 325295
  Complete submission text file 0001193125-26-104547.txt   16342850

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nktr-20251231.xsd EX-101.SCH 2125787
103 EXTRACTED XBRL INSTANCE DOCUMENT nktr-20251231_htm.xml XML 2980245
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-24006 | Film No.: 26749379
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)